ORIGINAL RESEARCH article
Front. Oncol.
Sec. Surgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1622215
This article is part of the Research TopicAdvances in Surgical Techniques and ML/DL-based Prognostic Biomarkers for Surgical and Adjuvant Therapies of Hepatobiliary and Pancreatic CancersView all 8 articles
Efficacy and Safety of the S-1, nab-Paclitaxel, and Gemcitabine Triplet Regimen in Patients with Resected Pancreatic Ductal Adenocarcinoma(PDAC)
Provisionally accepted
- 1Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China
- 2The Fifth Affiliated Hospital of Xinjiang Medical, Urumqi, China
- 3The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (containing nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDAC).： We retrospectively analyzed 3-year postoperative clinical data from 92 pancreatic ductal adenocarcinoma (PDAC) patients who underwent curative resection between March 2020 and March 2022. Participants were allocated to either a control group (n= 40) receiving nab-paclitaxel plus gemcitabine (nab-P/GEM) or an experimental group (n= 52) receiving S-1 plus nab-paclitaxel plus gemcitabine, with subsequent comparisons of overall survival (OS), disease-free survival (DFS), and adverse event (AE) incidence between groups.Results ： The experimental group demonstrated significantly prolonged median OS (28.9 vs. 20.9 months; HR 0.62, 95% CI 0.38-0.99; P = 0.049 by log-rank test) and DFS (19.5 vs. 13.6 months; HR 0.59, 95% CI 0.36-0.97; P = 0.036) compared to controls. Incidence of grade ≥3 AEs was significantly lower in the experimental group, including leukopenia (13.5% vs. 47.5%; P < 0.001) and neutropenia (15.4% vs. 70.0%; P < 0.001). Fewer patients required treatment discontinuation (1.9% vs. 12.5%) or dose modifications (13.5% vs. 65.0%) in the experimental group.The S-1/nab-paclitaxel/gemcitabine triplet regimen appears to improve survival outcomes while exhibiting potentially favorable tolerability as adjuvant therapy for resected PDAC.
Keywords: S-1, Nab-Paclitaxel, gemcitabine, Pancreatic Ductal Adenocarcinoma, Adjuvant chemotherapy
Received: 02 May 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Ran, Geng, Atigu, Nie and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xinjian Xu, The Fifth Affiliated Hospital of Xinjiang Medical, Urumqi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.